2026 Global: Cardiac Biomarkers-Competitive Review (2032) report
Description
The 2026 Global: Cardiac Biomarkers-Competitive Review (2032) report features the global market size and projected growth/decline data for the period 2021 and 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Cardiac biomarker testing is dominated by a core group of global suppliers whose assays underpin clinical triage for acute coronary syndromes and chronic heart conditions. Abbott Laboratories, headquartered in Abbott Park, United States, offers troponin I and related panels alongside its broad diagnostic portfolio. Roche Diagnostics, based in Basel, Switzerland, provides high-sensitivity troponin assays and BNP/NT-proBNP platforms widely deployed in hospital laboratories. Siemens Healthineers, with headquarters in Erlangen, Germany, supplies immunoassays and advanced analyzer platforms for cardiac markers, including troponin families and natriuretic peptides. DiaSorin, headquartered in Saluggia, Italy, develops LIAISON and related immunoassay systems for troponin and natriuretic peptide measurements, enabling high-throughput cardiovascular testing worldwide. These leaders drive standardization, quality control, and assay harmonization across hospital networks worldwide. Their portfolios increasingly integrate point-of-care capabilities globally. Industry collaboration and accreditation programs further encourage interoperability and comparability of results across instruments and laboratories. This trend supports evidence-based treatment decisions and research.
Ortho Clinical Diagnostics, headquartered in Raritan, United States, maintains a robust portfolio of troponin I and T assays, cardiomyopathy panels, and quality-control solutions that serve hospital laboratories and reference centers. Beckman Coulter Diagnostics, based in Brea, United States, complements central-lab platforms with Access immunoassays and hs-troponin chemistry, supporting rapid triage in emergency settings. Thermo Fisher Scientific, headquartered in Waltham, United States, provides a broad spectrum of diagnostic reagents, including cardiac troponin assays, BNP tests, and automation solutions that scale from clinical labs to population health studies. Together, these firms extend testing capacity across geographies, enabling standardized reporting and cross-platform comparability. Their strategies emphasize analytic performance, turnaround times, and seamless integration with laboratory information systems and electronic medical records, promoting harmonized data for cardiovascular risk assessment. Market dynamics reward early access to high-sensitivity troponin platforms, robust quality controls, and scalable solutions that integrate with hospital networks, enabling faster, evidence-based patient management.
Randox Laboratories, headquartered in Crumlin, United Kingdom, offers cardiac biomarker panels and high-sensitivity troponin assays designed for central laboratories and point-of-care applications. Quidel, based in San Diego, United States, provides rapid immunoassays for cardiac troponin and related markers through its Triage and AccuGen platforms, supporting fast triage decisions in emergency departments. Fujirebio, headquartered in Tokyo, Japan, supplies cardiac troponin I immunoassays and natriuretic peptide tests for clinical laboratories. Collectively, these firms complement the larger players by extending access to sensitive testing in resource-limited settings and by driving competitive pricing and innovation in assay chemistry, antibodies, and calibrators. The resulting landscape fosters ongoing evaluation of assay performance, standardization of reference materials, and harmonization of reporting units, all of which facilitate cross-site comparability of results, improved diagnostic confidence, and more precise patient management across cardiovascular care pathways. Regulatory alignment and comparative studies will sustain clinical adoption across diverse health systems worldwide, globally.
Cardiac biomarker testing is dominated by a core group of global suppliers whose assays underpin clinical triage for acute coronary syndromes and chronic heart conditions. Abbott Laboratories, headquartered in Abbott Park, United States, offers troponin I and related panels alongside its broad diagnostic portfolio. Roche Diagnostics, based in Basel, Switzerland, provides high-sensitivity troponin assays and BNP/NT-proBNP platforms widely deployed in hospital laboratories. Siemens Healthineers, with headquarters in Erlangen, Germany, supplies immunoassays and advanced analyzer platforms for cardiac markers, including troponin families and natriuretic peptides. DiaSorin, headquartered in Saluggia, Italy, develops LIAISON and related immunoassay systems for troponin and natriuretic peptide measurements, enabling high-throughput cardiovascular testing worldwide. These leaders drive standardization, quality control, and assay harmonization across hospital networks worldwide. Their portfolios increasingly integrate point-of-care capabilities globally. Industry collaboration and accreditation programs further encourage interoperability and comparability of results across instruments and laboratories. This trend supports evidence-based treatment decisions and research.
Ortho Clinical Diagnostics, headquartered in Raritan, United States, maintains a robust portfolio of troponin I and T assays, cardiomyopathy panels, and quality-control solutions that serve hospital laboratories and reference centers. Beckman Coulter Diagnostics, based in Brea, United States, complements central-lab platforms with Access immunoassays and hs-troponin chemistry, supporting rapid triage in emergency settings. Thermo Fisher Scientific, headquartered in Waltham, United States, provides a broad spectrum of diagnostic reagents, including cardiac troponin assays, BNP tests, and automation solutions that scale from clinical labs to population health studies. Together, these firms extend testing capacity across geographies, enabling standardized reporting and cross-platform comparability. Their strategies emphasize analytic performance, turnaround times, and seamless integration with laboratory information systems and electronic medical records, promoting harmonized data for cardiovascular risk assessment. Market dynamics reward early access to high-sensitivity troponin platforms, robust quality controls, and scalable solutions that integrate with hospital networks, enabling faster, evidence-based patient management.
Randox Laboratories, headquartered in Crumlin, United Kingdom, offers cardiac biomarker panels and high-sensitivity troponin assays designed for central laboratories and point-of-care applications. Quidel, based in San Diego, United States, provides rapid immunoassays for cardiac troponin and related markers through its Triage and AccuGen platforms, supporting fast triage decisions in emergency departments. Fujirebio, headquartered in Tokyo, Japan, supplies cardiac troponin I immunoassays and natriuretic peptide tests for clinical laboratories. Collectively, these firms complement the larger players by extending access to sensitive testing in resource-limited settings and by driving competitive pricing and innovation in assay chemistry, antibodies, and calibrators. The resulting landscape fosters ongoing evaluation of assay performance, standardization of reference materials, and harmonization of reporting units, all of which facilitate cross-site comparability of results, improved diagnostic confidence, and more precise patient management across cardiovascular care pathways. Regulatory alignment and comparative studies will sustain clinical adoption across diverse health systems worldwide, globally.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
